ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 7개 주요 막성 신증 시장을 조사 분석하여 각 지역 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.
목차
제1장 프리미엄 인사이트
제2장 막성 신증 주요 요약
제3장 막성 신증 경쟁 정보 분석
제4장 막성 신증 : 시장 개요
막성 신증 전체 시장 점유율 분포(2020년)
막성 신증 전체 시장 점유율 분포(2034년)
제5장 막성 신증 : 질환 배경과 개요
서론
징후와 증상
병태생리학
위험 요인
진단
제6장 환자 여정
제7장 막성 신증 역학과 환자 인구
역학 주요 조사 결과
전제조건과 근거 : 주요 7개 시장
역학 시나리오 : 주요 7개 시장
주요 7개 시장 막성 신증 역학 시나리오(2020년-2034년)
미국 역학
미국 막성 신증 역학 시나리오(2020년-2034년)
유럽 5개국 역학 : 국가별
독일 역학
프랑스 역학
이탈리아 역학
스페인 역학
영국 역학
일본 역학
제8장 치료 알고리즘, 현재 치료, 의료 행위
막성 신증 치료와 관리
막성 신증 치료 알고리즘
제9장 미충족 요구
제10장 막성 신증 치료 주요 평가항목
제11장 출시 제품
제12장 새로운 치료법
제13장 막성 신증 : 주요 7개 시장 분석
주요 조사 결과
주요 7개 막성 신증 시장 규모
주요 7개 막성 신증 시장 규모 : 치료법별
제14장 속성 분석
제15장 주요 7개 시장 : 시장 전망
미국 : 시장 규모
미국의 막성 신증 전체 시장 규모
미국의 막성 신증 시장 규모 : 치료법별
유럽 5개국 : 시장 규모와 전망
독일 시장 규모
독일의 막성 신증 전체 시장 규모
독일의 막성 신증 시장 규모 : 치료법별
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 시장 규모
영국의 막성 신증 전체 시장 규모
영국의 막성 신증 시장 규모 : 치료법별
일본 시장 전망
일본 시장 규모
제16장 막성 신증 접근 및 상환 개요
제17장 KOL(Key Opinion Leader)의 견해
제18장 시장 성장 촉진요인
제19장 시장 장벽
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight에 대해
LSH
영문 목차
영문목차
DelveInsight's "Membranous Nephropathy - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Membranous Nephropathy market report provides current treatment practices, emerging drugs, Membranous Nephropathy market share of the individual therapies, current and forecasted Membranous Nephropathy market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Membranous Nephropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2020-2034
Membranous Nephropathy Disease Understanding and Treatment Algorithm
The DelveInsight Membranous Nephropathy market report gives a thorough understanding of the Membranous Nephropathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Membranous Nephropathy.
Treatment
It covers the details of conventional and current medical therapies available in the Membranous Nephropathy market for the treatment of the condition. It also provides Membranous Nephropathy treatment algorithms and guidelines in the United States, Europe, and Japan.
Membranous Nephropathy Epidemiology
The Membranous Nephropathy epidemiology division provide insights about historical and current Membranous Nephropathy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Membranous Nephropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Membranous Nephropathy Epidemiology
The epidemiology segment also provides the Membranous Nephropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Membranous Nephropathy Drug Chapters
Drug chapter segment of the Membranous Nephropathy report encloses the detailed analysis of Membranous Nephropathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Membranous Nephropathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Membranous Nephropathy treatment.
Membranous Nephropathy Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Membranous Nephropathy treatment.
Membranous Nephropathy Market Outlook
The Membranous Nephropathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Membranous Nephropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Membranous Nephropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Membranous Nephropathy market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Membranous Nephropathy market in 7MM.
The United States Market Outlook
This section provides the total Membranous Nephropathy market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Membranous Nephropathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Membranous Nephropathy market size and market size by therapies in Japan is also mentioned.
Membranous Nephropathy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Membranous Nephropathy market or expected to get launched in the market during the study period 2020-2034. The analysis covers Membranous Nephropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Membranous Nephropathy Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Membranous Nephropathy key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Membranous Nephropathy emerging therapies.
Reimbursement Scenario in Membranous Nephropathy
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Membranous Nephropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Membranous Nephropathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Membranous Nephropathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
The report covers the descriptive overview of Membranous Nephropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Membranous Nephropathy epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Membranous Nephropathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Membranous Nephropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Membranous Nephropathy market
Report Highlights:
In the coming years, Membranous Nephropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Membranous Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Membranous Nephropathy. Launch of emerging therapies will significantly impact the Membranous Nephropathy market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Membranous Nephropathy
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Membranous Nephropathy Report Insights
Patient Population
Therapeutic Approaches
Membranous Nephropathy Pipeline Analysis
Membranous Nephropathy Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Membranous Nephropathy Report Key Strengths
11 Years Forecast
7MM Coverage
Membranous Nephropathy Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake
Membranous Nephropathy Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Questions:
Market Insights:
What was the Membranous Nephropathy market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Membranous Nephropathy total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Membranous Nephropathy market size during the forecast period (2024-2034)?
At what CAGR, the Membranous Nephropathy market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Membranous Nephropathy market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Membranous Nephropathy market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
What is the disease risk, burden and unmet needs of the Membranous Nephropathy?
What is the historical Membranous Nephropathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Membranous Nephropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Membranous Nephropathy?
Out of all 7MM countries, which country would have the highest prevalent population of Membranous Nephropathy during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Membranous Nephropathy treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Membranous Nephropathy in the USA, Europe, and Japan?
What are the Membranous Nephropathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Membranous Nephropathy?
How many therapies are developed by each company for Membranous Nephropathy treatment?
How many are emerging therapies in mid-stage, and late stage of development for Membranous Nephropathy treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Membranous Nephropathy therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Membranous Nephropathy and their status?
What are the key designations that have been granted for the emerging therapies for Membranous Nephropathy?
What are the global historical and forecasted market of Membranous Nephropathy?
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Membranous Nephropathy market
To understand the future market competition in the Membranous Nephropathy market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Membranous Nephropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Membranous Nephropathy market
To understand the future market competition in the Membranous Nephropathy market
Table of Contents
1. Key Insights
2. Executive Summary of Membranous Nephropathy
3. Competitive Intelligence Analysis for Membranous Nephropathy
4. Membranous Nephropathy: Market Overview at a Glance
4.1. Membranous Nephropathy Total Market Share (%) Distribution in 2020
4.2. Membranous Nephropathy Total Market Share (%) Distribution in 2034
5. Membranous Nephropathy: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Membranous Nephropathy Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Membranous Nephropathy Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
7.4.1. Membranous Nephropathy Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Membranous Nephropathy Epidemiology Scenario in Germany (2020-2034)
7.5.2. France Epidemiology
7.5.2.1. Membranous Nephropathy Epidemiology Scenario in France (2020-2034)
7.5.3. Italy Epidemiology
7.5.3.1. Membranous Nephropathy Epidemiology Scenario in Italy (2020-2034)
7.5.4. Spain Epidemiology
7.5.4.1. Membranous Nephropathy Epidemiology Scenario in Spain (2020-2034)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Membranous Nephropathy Epidemiology Scenario in the United Kingdom (2020-2034)
7.5.6. Japan Epidemiology
7.5.6.1. Membranous Nephropathy Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Membranous Nephropathy Treatment and Management
8.2. Membranous Nephropathy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Membranous Nephropathy Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Membranous Nephropathy: Seven Major Market Analysis
13.1. Key Findings
13.2. Membranous Nephropathy Market Size in 7MM
13.3. Membranous Nephropathy Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Membranous Nephropathy Total Market Size in the United States
15.1.2. Membranous Nephropathy Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Membranous Nephropathy Total Market Size in Germany
15.3.2. Membranous Nephropathy Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Membranous Nephropathy Total Market Size in France
15.4.2. Membranous Nephropathy Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Membranous Nephropathy Total Market Size in Italy
15.5.2. Membranous Nephropathy Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Membranous Nephropathy Total Market Size in Spain
15.6.2. Membranous Nephropathy Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Membranous Nephropathy Total Market Size in the United Kingdom
15.7.2. Membranous Nephropathy Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Membranous Nephropathy Total Market Size in Japan
15.8.3. Membranous Nephropathy Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Membranous Nephropathy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
The table of contents is not exhaustive; the final content may vary.
